Extended Data Fig. 6: In vivo experiments with additional B16 PAK4 KO and rescue clones and CD8 depletion validation.
a, Tumour growth curves for B16 PAK4 KO 8.1 tumours treated with isotype (blue, n = 10) or anti-PD-1 (red, n = 12) (P= 0.00024, day 15). b, Tumour growth curves for B16 PAK4 KO 8.2 tumours treated with isotype (blue, n = 10) or anti-PD-1 (red, n = 10) (P= 0.02, day 15). In both PAK4 KO cell lines anti-PD-1 treated tumours showed decreased tumour growth compared to untreated tumours. c, Tumour growth curves for B16 8.1 PAK4 rescue tumours treated with isotype (blue, n = 5) or anti-PD-1 (red, n = 5). Anti-PD-1 treatment did not result in any significant anti-tumour efficacy (P= 0.80, day 15). d, Flow cytometry analysis of CD8 positive splenocytes after CD8 depletion. Left panel show splenocytes pattern without anti-CD8 treatment (CD8 population = 18.9%) while middle and right panel show splenocytes derived from two independent mice treated with anti-CD8 antibody (CD8 population = 0.77% and 0.50% respectively). Plotting the mean +/- s.e.m a-c. Statistical significance and correction for multiple comparisons was calculated using Holm-Sidak method a-c. Raw data is provided as a Source Data file a-c. *P <0.05, **P < 0.01, ***P <0.001, ****P < 0.0001. ns, not significant.
